Bezafibrates cause moderate, reversible impairment in renal function in patients without prior renal disease

Nephron - Clinical Practice

Volumn 100, Issue 4, 2005, Pages

  Charach, Gideon ^a,b   Grosskopf, Itamar ^a   Rotmensch, Heschi H ^a   Kitzis, Ilan ^a   Weintraub, Moshe ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b Department of Internal Medicine C ^*  (Israel)

Author keywords

Creatinine; Creatinine clearance; Fibrates; Myoglobin; Renal function; Rhabdomyolysis

Indexed keywords

BEZAFIBRATE; CREATINE KINASE; CREATININE; MYOGLOBIN;

ADULT; ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DOSE RESPONSE; FEMALE; HUMAN; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; UREA BLOOD LEVEL;

ADULT; AGED; BEZAFIBRATE; CREATINE KINASE; CREATININE; FEMALE; HUMANS; KIDNEY; MALE; MIDDLE AGED; MUSCLE, SKELETAL; MYOGLOBINURIA; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 21344451405     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085291     Document Type: Article

References (21)

1. Ballantyne CM, Grundy SM, Oberman A, Kreisberg RA, Havel RJ, Frost PH, Haffner SM: Hyperlipidemia: Diagnostic and therapeutic perspectives. J Clin Endocrinol Metab 2000;85:2089-2112.
2. Austin MA, Hokanson JE, Edwards KL: Hypertriglycidemia as a cardiovascular risk factor. Am J Cardiol 1998;81:7B-12B.
3. Johansson S, Wilhelmsen L, Lappas G, Rosengen A: High lipid levels and coronary disease in woman in Goteborg - Outcome and secular trends: a prospective 19-year follow-up in the BEDA* study. Eur Heart J 2003;24:704-716.
4. Frick MH, Syvanne M, Nieminen MS, Kauma H, Majahalme S, Virtanen V, Kesaniemi YA, Pasternack A, Taskinen MR: Prevention of the angiographic progression of coronary and veingraft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation 1997;96:2113-2114.
5. Ericsson CG, Hamsten A, Nilsson J, Grip L, Svane B, de Faire U: Angiographic assessment of effects of bezafibrate on progress of coronary artery disease in young male postinfarction patient. Lancet 1996;347:849-853.
6. Haffner SM: Secondary prevention of coronary heart disease: The role of fibric. Circulation 2000;102:2-4.
7. Scheen AJ: Clinical study of the month. Usefulness of increasing HDL cholesterol in secondary prevention of coronary heart disease results of VA-HIT study. Rev Med Liege 1999;54:773-775.
8. Elisaf M: Effects of fibrates on serum metabolic parameters. Curr Med Res Opin 2002;18:269-276.
9. Devuyst O, Goffin E, Pirson Y, Van Ypersele de Strihou C: Creatinine rise after fibrate therapy in renal graft recipients. Lancet 1993;341:840.
10. De Lorgeril M, Boissonn P, Bizollon CA, Guidollet J, Faucon G, Guichard JP, Levy-Prades-Sauron R, Renaud S, Dureau G: Pharmacokinetics of cyclosporine in hyperlipidemic long-term survivors of heart transplantation. Lack of interaction with the lipid-lowering agent, fenofibrate. Eur J Clin Pharmacol 1992;43:161-165.
11. Ellen RL, McPherson R: Long-term efficacy and safety of fenofibrate and statin in the treatment of combined hyperlipidemia. Am J Cardiol 1998;81:60B-65B.
12. Dierkes J, Westphal S, Luley C: Serum homocysteine increases after therapy with fenofibrate and bezafibrate. Lancet 1999;354:219-220.
13. Hottelart C, el Esper N, Achard JM, Pruna A, Fournier A: Fenofibrate increases but does not change glomerular filtration rate in patients with mild renal insufficiency. Nephrologie 1999;20:41-44.
14. Lipscombe J, Lewis GF, Cattran D, Bargman JM: Deterioration of renal function associated with fibrate therapy. Clin Nephrol 2001;55:39-44.
15. Ritter JL, Nabulsi S: Fenofibrate-induced elevation in serum creatinine. Pharmacotherapy 2001;21:1145-1149.
16. Barbir M, Hunt B, Kushwaha S, Kehely A, Prescot R, Thompson GR, Mitchell A, Yacoub M: Maxepa versus bezafibrate in hyperlipidemic cardiac transplant recipients. Am J Cardiol 1992;70:1596-1601.
17. Broeders N, Knoop C, Antoine M, Tielemans C, Abramowicz D: Fibrate-induced increase in blood urea and creatinine: Is gemfibrozil the only innocuous agent? Nephrol Dial Transplant 2000;15:1993-1999.
18. Magarian GJ, Lucas LM, Colley C: Gemfibrozil-induced myopathy. Arch Intern Med 1991;151:1873-1874.
19. Holt S, Moore K: Pathogenesis of renal failure in rhabdomyolysis: The role of myoglobin. Exp Nephrol 2000;8:72-76.
20. Loun B, Astles R, Copeland KR, Sedor FA: Adaptation of quantitative immunoassay for urine myoglobin. Predictor in detecting renal dysfunction. Am J Clin Pathol 1996;105:479-486.
21. Vetterlin F, Hoffman F, Pedina J, Neckel M, Schmidt G: Disturbances in renal microcirculation induced by myoglobin and hemorrhagic hypotension in anesthetized rat. Am J Physiol 1995;265:F839-F846.